Loading
Life sciences · Journal article
Cell Death and Disease · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK)-fusion oncogene respond remarkably well to ALK-tyrosine kinase inhibitor (ALK-TKI) therapies. However, the emergence of resistance remains a major challenge in long-term ALK-TKI treatment. The aim of this study was to elucidate the factors contributing to the formation of drug-tolerant persister cells (DTPs) in ALK-positive lung cancer and to explore therapeutic strategies for targeting these cells. To this end, we performed genome-wide CRISPR-Cas9 knockout screening using patient-derived ALK-positive NSCLC cells. This screening identified the apoptosis-associated factor BMF as a key regulator of DTP formation. BMF expression increased within 24 h of ALK-TKI treatment or dual ERK and PI3K pathway inhibition. BMF-knockout cells exhibited impaired apoptosis and an increased DTP population following ALK-TKI treatment. This suggests that BMF plays a pivotal role in ALK-TKI-induced apoptosis induction. Pharmacological inhibition or siRNA-mediated knockdown of MCL-1 with ALK-TKI treatment effectively induced apoptosis and eliminated BMF knocked-out cells. Furthermore, siRNA-mediated knockdown of the transcription factor FOXO1 increased BMF expression, suggesting that FOXO1-mediated signaling contributes to the suppression of BMF. Thus, FOXO1 inhibition could enhance the efficacy of ALK-targeted therapies. Notably, the role of BMF observed in ALK-positive lung cancer models was recapitulated in ROS1-positive cell lines. Overall, BMF plays a critical role in apoptosis induction and is upregulated during targeted therapy for ALK/ROS1-positive lung cancer. BMF loss promotes DTP formation and contributes to therapeutic resistance. Targeting MCL-1 or FOXO1 may be a promising strategy for eliminating DTP cells and enhancing the efficacy of ALK/ROS1-TKIs.